Topical antifungal bioequivalence
Executive Summary
Studies will require a "significantly higher" number of patients than originally anticipated, FDA says. According to one FDA official, the agency had initially estimated that only 60 patients would be adequate. An FDA topical antifungal guidance, issued March 15, suggested that the number of patients needed in clinical trials to show bioequivalence should be determined with "statistical consultation." FDA is planning a workshop in the fall to discuss what will be required to show bioequivalence to reference topical antifungal products.
You may also be interested in...
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.